Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda.

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer. Business Wire Jun 24, 2025, 11:00:00 AM.

Johnson & Johnson's hopes of quickly building its new cancer drug Rybrevant into a $5 billion product have been undermined by an FDA decision.